Natura and Solazyme Announce Sales Agreement for Microalgae Oil
June 09 2015 - 9:00AM
Business Wire
Solazyme´s AlgaPūrTM Microalgae Oil to be
featured in multiple skincare product lines
Natura Cosméticos S.A. (BM&FBOVESPA:NATU3) one of Latin
America's largest cosmetics and personal care products company, and
Solazyme, Inc. (NASDAQ:SZYM), a renewable oils and ingredients
company, announced today that after successfully completing testing
and product validation phases over the past year using Solazyme’s
oils, Natura is purchasing Solazyme’s high-performance AlgaPūrTM
Microalgae Oil, which will be incorporated into Natura’s multiple
product lines.
Solazyme’s microalgae oils are produced in a matter of days
using a fermentation process designed to produce oils of the
highest purity, performance and sustainability. Some of the
benefits of using AlgaPūr oils for skin care are higher hydration
levels, a silky but not greasy skin feel, mildness on the skin,
neutral color and odor, and improved shelf life.
Walfredo Linhares, General Manager of Solazyme Bunge Renewable
Oils in Brazil, said, "We believe high performance and
sustainability belong together. Natura is a leader in innovation
and globally recognized for their sustainability efforts. We are
very happy to work together to deliver better products for
consumers and for our planet."
Natura and Solazyme have been working together for two years on
several projects on joint efforts to develop new formulations with
Solazyme’s microalgae oils. “We are always looking for ingredients
from renewable sources and technologies inspired in the nature,
targeting low environmental impact processes and high performance
solutions," says Daniel Gonzaga, Director of Advanced Research of
Natura. "Solazyme microalgae oil that will compose some of our
products are a sustainable alternative for new formulations
development," he concludes.
Solazyme produces sustainable high performance ingredients for
multiple markets and its joint venture facility is located in São
Paulo State, in partnership with Bunge.
About Solazyme, Inc.
Solazyme, Inc. develops and sells high-performance oils and
ingredients that are better for people and better for the planet.
Starting with microalgae, the world’s original oil producer,
Solazyme creates innovative, sustainable, high-performance
products. These include renewable oils and ingredients that serve
as the foundation for healthier foods; high-performance industrial
products; unique home and personal care solutions; and more
sustainable fuels. Headquartered in South San Francisco, Solazyme’s
mission is to solve some of the world’s biggest problems with one
of the world’s smallest and earliest life forms: microalgae.
For additional information, please visit Solazyme’s website
at www.solazyme.com.
About Natura
Founded in 1969, Natura is the biggest Brazilian multinational
of cosmetics and health and beauty products. Leader in the direct
sales industry in Brazil, it reported net revenue totaling R$ 7.4
billion in 2014, it has 7,000 employees, 1.7 million consultants
and operations in Argentina, Bolivia, Chile, Mexico, Peru, Colombia
and France.
Largest B Corp company in the world, it was the first
publicly-held company to receive the certification, in December
2014, which reinforces its transparent and sustainable operations
on social, environmental and economic aspects. The company’s
structure is made up of plants in Cajamar (SP) and Benevides (PA),
eight distribution centers in Brazil, one HUB in Itupeva, in
addition to Research and Technology centers in São Paulo (SP),
Manaus (AM) and New York (USA). It holds 65% of the Australian
manufacturer of cosmetics Aesop, with stores in countries in
Oceania, Asia, Europe and North America. Natura’s products can be
purchased through Revista Natura (product catalog)
or Rede Natura at www.redenatura.net. To find a Natura
Consultant nearby, consumers can send a free SMS with the word for
Natura 28128. For more information about the company, visit
www.natura.com.br and check their profiles on the following social
networks: Linkedin, Facebook, Twitter and YouTube.
Forward Looking Statements
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 about Solazyme, including statements that involve risks and
uncertainties concerning: its commercialization and production
plans; meeting commercialization and technology targets; successful
product trials and market acceptance of its products; and
Solazyme’s ability to maintain its relationships with its partners.
When used in this press release, the words “will”, “expects”,
“intends” and other similar expressions and any other statements
that are not historical facts are intended to identify those
assertions as forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any such
statement may be influenced by a variety of factors, many of which
are beyond the control of Solazyme, that could cause actual
outcomes and results to be materially different from those
projected, described, expressed or implied in this press release
due to a number of risks and uncertainties. Potential risks and
uncertainties include, among others: Solazyme’s limited operating
history; its limited history in commercializing products;
implementation risk in deploying new technologies; its limited
experience in constructing, ramping up and operating commercial
manufacturing facilities; its ability to sell its products at a
profit; delays related to construction, start-up and ramp-up of
production facilities; its ability to manage operational costs at
production facilities; its ability to enter into and maintain
strategic collaborations; its ability to obtain requisite
regulatory approvals; and its access, on favorable terms, to any
required financing. Accordingly, no assurances can be given that
any of the events anticipated by the forward-looking statements
will transpire or occur, or if any of them do so, what impact they
will have on the results of operations or financial condition of
Solazyme.
In addition, please refer to the documents that Solazyme, Inc.
files with the Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q, as updated from time to time, for a
discussion of these and other risks. You are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date of this press release. Solazyme is not under any duty
to update any of the information in this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150609005629/en/
Solazyme, Inc.Genet Garamendi, 650-780-4777Corporate
Communicationspress@solazyme.com